Interestingly, there are no Big Pharma companies listed in the “Magnificent Seven.” Consequently, perfectly good companies like Pfizer (NYSE:PFE) are being overlooked, but that’s not bad news at all. If you appreciate a good value and like to collect dividends, stick around as today’s Pfizer stock analysis will bring you a “magnificent” pick for 2024. Now, I’m not going to claim that Pfizer is a problem-free company. It’s important to be aware of Pfizer’s challenges. However, without problems, there would b ...

Pfizer (PFE 0.22%) celebrates its 175th anniversary this year, so the pharma giant has a long history. But the drugmaker actually jumped into the global spotlight not long ago when it launched its blockbuster coronavirus vaccine, Comirnaty, followed by top-selling COVID treatment Paxlovid. These two products helped Pfizer reach a record $100 billion in annual revenue in 2022.The past year, though, has been a difficult one for the big pharma company. Demand for coronavirus products has been on the decline, w ...

Michael M. Santiago Written by Sam Kovacs. Introduction The pendulum of the market always swings. In just 2 years, Pfizer Inc. (NYSE:PFE) has gone from its ATH to the lowest price it has recorded in over 10 years. We've been watching it all come down, as by the time February 2022 hit, we had sold all of our Pfizer position, after having accumulated it in 2020 prior to the vaccine announcement (source here and here). When in December 2021, we said selling PFE was a good idea, this was met with quite a bit of ...

Pfizer Inc. (NYSE:PFE) Q4 2023 Results Conference Call January 30, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer David Denton - Chief Financial Officer Aamir Malik - Executive VP & Chief U.S. Commercial Officer Alexandre de Germay - Executive VP & Chief International Commercial Officer Mikael Dolsten - Chief Scientific Officer and President of Research & Development Chris Boshoff - Executive VP & Chief Oncolo ...

Shares of Pfizer (PFE -0.64%) jumped as much as 3.2% higher on Tuesday morning before giving up all of the gains and then some. The pharma stock was down by 0.6% as of 12:05 p.m. ET.These gyrations came after Pfizer announced its fourth-quarter and full-year results before the opening bell. The company reported Q4 revenue of $14.2 billion. Although this was a 41% year-over-year decline, it still topped Wall Street's consensus revenue estimate of $13.3 billion.Pfizer posted a Q4 loss of nearly $3.4 billion, ...

For the quarter ended December 2023, Pfizer (PFE) reported revenue of $14.25 billion, down 41.3% over the same period last year. EPS came in at $0.10, compared to $1.14 in the year-ago quarter.The reported revenue represents a surprise of -0.80% over the Zacks Consensus Estimate of $14.36 billion. With the consensus EPS estimate being -$0.19, the EPS surprise was +152.63%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...

Pfizer (PFE) reported fourth-quarter 2023 adjusted earnings per share of 10 cents in contrast to the Zacks Consensus Estimate of a loss of 19 cents per share. In the year-ago quarter, the company had recorded earnings of $1.41 per share.Revenues came in at $14.25 billion, down 41% from the year-ago quarter on a reported basis, reflecting an operational decline of 42% but a currency benefit of 1%. Total revenues missed the Zacks Consensus Estimate of $14.37 billion.The revenue decline, as expected, was due t ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Pfizer Inc (NYSE:PFE) entered the earnings ring before the bell this morning, announcing fourth-quarter earnings of 10 cents per share, which is higher than analysts' anticipated losses of 22 cents. Meanwhile, revenue of $14.25 billion came in lower than the expected $14.42 billion. In regard to 2024, the pharmaceutical giant reaffirmed its forecast. Pfizer stock has erased its earlier gains, currently down 1.7% at $27.02. The stock ran up to recent pressure at its 20-day moving average before the reversal, ...

Key TakeawaysPfizer reported a surprise profit in the fourth quarter despite double-digit revenue contraction.Adjusted income came in at $593 million or 10 cents per diluted share versus a loss expected by analysts.Fourth quarter revenue fell 41% from a year ago to $14.2 billion.Pfizer Inc. (PFE) delivered a surprise profit in the fourth quarter despite a double-digit contraction in revenue. Pfizer shares were up 1.8% in early trading Tuesday following the release.While analysts expected wider quarterly los ...